Development and Validation of Coding Algorithms to Identify Patients with Incident Non-Small Cell Lung Cancer in United States Healthcare Claims Data

被引:2
|
作者
Beyrer, Julie [1 ,3 ]
Nelson, David R. [1 ]
Sheffield, Kristin M. [1 ]
Huang, Yu-Jing [1 ]
Lau, Yiu-Keung [1 ]
Hincapie, Ana L. [2 ]
机构
[1] Eli Lilly & Co, Indianapolis, IN USA
[2] Univ Cincinnati James L Winkle, Coll Pharm, Cincinnati, OH USA
[3] Eli Lilly & Co, Lilly Corp Ctr, Indianapolis, IN 46285 USA
来源
CLINICAL EPIDEMIOLOGY | 2023年 / 15卷
关键词
algorithm; machine learning; medicare claims; non-small cell lung cancer; positive predictive value; sensitivity; validation;
D O I
10.2147/CLEP.S389824
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Purpose: We sought to develop and validate an incident non-small cell lung cancer (NSCLC) algorithm for United States (US) healthcare claims data. Diagnoses and procedures, but not medications, were incorporated to support longer-term relevance and reliability. Methods: Patients with newly diagnosed NSCLC per Surveillance, Epidemiology, and End Results (SEER) served as cases. Controls included newly diagnosed small-cell lung cancer and other lung cancers, and two 5% random samples for other cancer and without cancer. Algorithms derived from logistic regression and machine learning methods used the entire sample (Approach A) or started with a previous algorithm for those with lung cancer (Approach B). Sensitivity, specificity, positive predictive values (PPV), negative predictive values, and F-scores (compared for 1000 bootstrap samples) were calculated. Misclassification was evaluated by calculating the odds of selection by the algorithm among true positives and true negatives.Results: The best performing algorithm utilized neural networks (Approach B). A 10-variable point-score algorithm was derived from logistic regression (Approach B); sensitivity was 77.69% and PPV = 67.61% (F-score = 72.30%). This algorithm was less sensitive for patients >= 80 years old, with Medicare follow-up time <3 months, or missing SEER data on stage, laterality, or site and less specific for patients with SEER primary site of main bronchus, SEER summary stage 2000 regional by direct extension only, or pre-index chronic pulmonary disease.Conclusion: Our study developed and validated a practical, 10-variable, point-based algorithm for identifying incident NSCLC cases in a US claims database based on a previously validated incident lung cancer algorithm.
引用
收藏
页码:73 / 89
页数:17
相关论文
共 50 条
  • [41] Validation of algorithms to identify colorectal cancer patients from administrative claims data of a Japanese hospital
    Hirano, Takahiro
    Negishi, Makiko
    Kuwatsuru, Yoshiki
    Arai, Masafumi
    Wakabayashi, Ryozo
    Saito, Naoko
    Kuwatsuru, Ryohei
    [J]. BMC HEALTH SERVICES RESEARCH, 2023, 23 (01)
  • [42] Validation of algorithms to identify colorectal cancer patients from administrative claims data of a Japanese hospital
    Takahiro Hirano
    Makiko Negishi
    Yoshiki Kuwatsuru
    Masafumi Arai
    Ryozo Wakabayashi
    Naoko Saito
    Ryohei Kuwatsuru
    [J]. BMC Health Services Research, 23
  • [43] Exercise in Patients with Non-Small Cell Lung Cancer
    Kuehr, Lea
    Wiskemann, Joachim
    Abel, Ulrich
    Ulrich, Cornelia M.
    Hummler, Simone
    Thomas, Michael
    [J]. MEDICINE AND SCIENCE IN SPORTS AND EXERCISE, 2014, 46 (04): : 656 - 663
  • [44] Early assessment of sotorasib for treatment of patients with advanced non-small cell lung cancer using real-world data in the United States
    Aran, Dvir
    Shahoha, Meishar
    Rosenberg-Katz, Keren
    Amar-Farkash, Shlomit
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [45] REAL-WORLD TREATMENT OF PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER: RESULTS OF A CLAIMS DATA STUDY OF PATIENTS IN GERMANY
    Cizova, D.
    Gottschalk, F.
    Mueller, S.
    Myers, D.
    Wilke, T.
    [J]. VALUE IN HEALTH, 2018, 21 : S22 - S22
  • [46] Disparities in biomarker testing practices in patients with metastatic non-small cell lung cancer (NSCLC) in the United States (US)
    Dennis, Michael J.
    Abrahami, Devin
    Vieira, Maria Cecilia
    Benjumea, Darrin
    Boyd, Marley
    Shao, Anran
    Duncan, Kirsten
    Kelton, John
    Patel, Sandip P.
    [J]. CANCER RESEARCH, 2024, 84 (06)
  • [47] Biomarker Testing Trends and Treatment Patterns in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients in the United States
    Chu, L.
    Corvino, F.
    Yi, J.
    Zivkovic, M.
    Wong, W.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2235 - S2236
  • [48] A methodology to extract outcomes from routine healthcare data for patients with locally advanced non-small cell lung cancer
    Swee-Ling Wong
    Kate Ricketts
    Gary Royle
    Matt Williams
    Ruheena Mendes
    [J]. BMC Health Services Research, 18
  • [49] RACIAL/ETHNIC VARIATION AMONG NON-SMALL CELL LUNG CANCER (NSCLC) PATIENTS IN THE UNITED STATES DEPARTMENT OF DEFENSE
    Carter, Corey A.
    Satram-Hoang, Sacha
    Brzezniak, Christina
    Gunuganti, Ashok
    Reyes, Carolina
    Goertz, Hans-Peter
    Gallagher, Christopher
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S995 - S996
  • [50] Current Treatment Algorithms for Patients with Metastatic Non-Small Cell, Non-Squamous Lung Cancer
    Melosky, Barbara
    [J]. FRONTIERS IN ONCOLOGY, 2017, 7